Adriane D M Vorselaars1, Coline H M van Moorsel2, Pieter Zanen3, Henk J T Ruven4, Anke M E Claessen5, Heleen van Velzen-Blad5, Jan C Grutters2. 1. Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands. Electronic address: a.vorselaars@antoniusziekenhuis.nl. 2. Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands; Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands. 3. Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands. 4. Department of Clinical Chemistry, St. Antonius Hospital Nieuwegein, The Netherlands. 5. Department of Medical Microbiology and Immunology, St Antonius Hospital, Nieuwegein, The Netherlands.
Abstract
INTRODUCTION: In sarcoidosis, the search for disease activity markers that correlate with treatment response is ongoing. The aim of this study was to investigate the pattern of two proposed markers, serum angiotensin-converting enzyme (ACE) and soluble IL-2 receptor (sIL-2R) during methotrexate (MTX) therapy in sarcoidosis patients. MATERIALS AND METHODS: We analysed 114 sarcoidosis patients who used MTX for six months, consisting of a subgroup of 76 patients with a pulmonary indication for treatment and a subgroup of 38 patients with an extra-pulmonary indication. ACE and sIL-2R serum levels were measured at baseline and after six months of treatment. Correlation coefficients (R) and odds ratios (ORs) were calculated to study the correlation and predictive effect of serum ACE and sIL-2R levels for pulmonary improvement. RESULTS: High baseline levels of ACE correlated significantly with lung function improvement after treatment (R = 0.45, p < 0.0001; stronger in the pulmonary subgroup R 0.57, p < 0.0001). ACE baseline levels >90 U/l predicted a 10% improvement in overall lung function (OR 3.55; CI 1.34-9.38), with the highest prediction level for 10% improvement in DLCO (OR 4.63; CI 1.23-17.4). After six months of MTX, mean ACE decreased with 17.2 U/l (p < 0.0001) and sIL-2R with 1850 pg/ml (p < 0.0001). Decreases in both ACE and sIL-2R correlated with an increase in lung function. The strongest correlation was found with change in DLCO in the pulmonary subgroup (ACE R = 0.63, P < 0.0001; sIL-2R R = 0.56, P < 0.0001). CONCLUSION: Baseline and serial serum ACE and sIL-2R levels correlate well with lung function improvement during MTX treatment. Serial measurements of these biomarkers are helpful in monitoring treatment effects in sarcoidosis patients.
INTRODUCTION: In sarcoidosis, the search for disease activity markers that correlate with treatment response is ongoing. The aim of this study was to investigate the pattern of two proposed markers, serum angiotensin-converting enzyme (ACE) and soluble IL-2 receptor (sIL-2R) during methotrexate (MTX) therapy in sarcoidosispatients. MATERIALS AND METHODS: We analysed 114 sarcoidosispatients who used MTX for six months, consisting of a subgroup of 76 patients with a pulmonary indication for treatment and a subgroup of 38 patients with an extra-pulmonary indication. ACE and sIL-2R serum levels were measured at baseline and after six months of treatment. Correlation coefficients (R) and odds ratios (ORs) were calculated to study the correlation and predictive effect of serum ACE and sIL-2R levels for pulmonary improvement. RESULTS: High baseline levels of ACE correlated significantly with lung function improvement after treatment (R = 0.45, p < 0.0001; stronger in the pulmonary subgroup R 0.57, p < 0.0001). ACE baseline levels >90 U/l predicted a 10% improvement in overall lung function (OR 3.55; CI 1.34-9.38), with the highest prediction level for 10% improvement in DLCO (OR 4.63; CI 1.23-17.4). After six months of MTX, mean ACE decreased with 17.2 U/l (p < 0.0001) and sIL-2R with 1850 pg/ml (p < 0.0001). Decreases in both ACE and sIL-2R correlated with an increase in lung function. The strongest correlation was found with change in DLCO in the pulmonary subgroup (ACE R = 0.63, P < 0.0001; sIL-2R R = 0.56, P < 0.0001). CONCLUSION: Baseline and serial serum ACE and sIL-2R levels correlate well with lung function improvement during MTX treatment. Serial measurements of these biomarkers are helpful in monitoring treatment effects in sarcoidosispatients.
Authors: Maria Vincenza Polito; Stephan Stoebe; Leonard Leifels; Patrick Stumpp; Kilian Solty; Gennaro Galasso; Federico Piscione; Ulrich Laufs; Karin Klingel; Andreas Hagendorff Journal: Clin Res Cardiol Date: 2018-05-18 Impact factor: 5.460
Authors: David Birnie; Rob S B Beanlands; Pablo Nery; Shawn D Aaron; Daniel A Culver; Robert A DeKemp; Lorne Gula; Andrew Ha; Jeffery S Healey; Yuko Inoue; Mark A Judson; Daniel Juneau; Kengo Kusano; Russell Quinn; Lena Rivard; Mustafa Toma; Amanda Varnava; George Wells; Melissa Wickremasinghe; Jordana Kron Journal: Am Heart J Date: 2019-10-20 Impact factor: 4.749
Authors: Wilhelmina Maria Cornelia Timmermans; Jan Alexander Michael van Laar; Petrus Martinus van Hagen; Menno Cornelis van Zelm Journal: Clin Transl Immunology Date: 2016-12-16